[{"id":"eaa7905b-c46a-428c-a893-85ea9fe3af9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441956","created_at":"2022-07-01T20:56:47.697Z","updated_at":"2024-07-02T16:35:10.474Z","phase":"Phase 1","brief_title":"TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05441956","lead_sponsor":"Shenzhen TargetRx, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e deulorlatinib (TGRX-326)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-04-10"}]